Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes

John N. Fain, Alie Kanu, Suleiman Bahouth, George S.M. Cowan, M. Lloyd Hiler

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The addition of atrial natriuretic peptide (ANP) to isolated human adipocytes in primary culture from very obese individuals resulted in an inhibition of leptin release after a 24- or 48-hr incubation. There was also an inhibition of leptin release by isoproterenol (ISO) that was partially reversed by insulin, whereas the inhibition due to ANP was unaffected. Similar results were seen with N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulphonamide (H-89), which is a cell-permeable inhibitor of protein kinase A. H-89 markedly reduced the effects of ISO on both lipolysis and leptin release without affecting the stimulation of lipolysis or the inhibition of leptin release due to ANP. Inhibition of endogenous nitric oxide formation using Nω-nitro-L-arginine resulted in a 20% increase in leptin release over 48hr, which suggests that the nitric oxide/cyclic GMP pathway might play a small role in the regulation of endogenous leptin release. Similarly, the addition of the nitric oxide donor (Z)-1-[2-aminoethyl)-N-(2-aminoethyl)diazen-1-ium-1,2-diolate (DETA NONOate) at 0.1 or 1μM to explants of human adipose tissue enhanced lipolysis by 29%. Our data demonstrate that the lipolytic effect of ANP is probably secondary to stimulation of cyclic GMP accumulation in human adipocytes, and this is accompanied by an inhibition of leptin release.

Original languageEnglish (US)
Pages (from-to)1883-1888
Number of pages6
JournalBiochemical Pharmacology
Volume65
Issue number11
DOIs
StatePublished - Jun 1 2003

Fingerprint

Atrial Natriuretic Factor
Leptin
Adipocytes
Lipolysis
Cyclic GMP
Isoproterenol
Nitric Oxide
Nitric Oxide Donors
Cyclic AMP-Dependent Protein Kinases
Arginine
Adipose Tissue
Insulin
Tissue

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. / Fain, John N.; Kanu, Alie; Bahouth, Suleiman; Cowan, George S.M.; Hiler, M. Lloyd.

In: Biochemical Pharmacology, Vol. 65, No. 11, 01.06.2003, p. 1883-1888.

Research output: Contribution to journalArticle

Fain, John N. ; Kanu, Alie ; Bahouth, Suleiman ; Cowan, George S.M. ; Hiler, M. Lloyd. / Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. In: Biochemical Pharmacology. 2003 ; Vol. 65, No. 11. pp. 1883-1888.
@article{e78252383a6c416886ab2053fd9580cc,
title = "Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes",
abstract = "The addition of atrial natriuretic peptide (ANP) to isolated human adipocytes in primary culture from very obese individuals resulted in an inhibition of leptin release after a 24- or 48-hr incubation. There was also an inhibition of leptin release by isoproterenol (ISO) that was partially reversed by insulin, whereas the inhibition due to ANP was unaffected. Similar results were seen with N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulphonamide (H-89), which is a cell-permeable inhibitor of protein kinase A. H-89 markedly reduced the effects of ISO on both lipolysis and leptin release without affecting the stimulation of lipolysis or the inhibition of leptin release due to ANP. Inhibition of endogenous nitric oxide formation using Nω-nitro-L-arginine resulted in a 20{\%} increase in leptin release over 48hr, which suggests that the nitric oxide/cyclic GMP pathway might play a small role in the regulation of endogenous leptin release. Similarly, the addition of the nitric oxide donor (Z)-1-[2-aminoethyl)-N-(2-aminoethyl)diazen-1-ium-1,2-diolate (DETA NONOate) at 0.1 or 1μM to explants of human adipose tissue enhanced lipolysis by 29{\%}. Our data demonstrate that the lipolytic effect of ANP is probably secondary to stimulation of cyclic GMP accumulation in human adipocytes, and this is accompanied by an inhibition of leptin release.",
author = "Fain, {John N.} and Alie Kanu and Suleiman Bahouth and Cowan, {George S.M.} and Hiler, {M. Lloyd}",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0006-2952(03)00154-0",
language = "English (US)",
volume = "65",
pages = "1883--1888",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes

AU - Fain, John N.

AU - Kanu, Alie

AU - Bahouth, Suleiman

AU - Cowan, George S.M.

AU - Hiler, M. Lloyd

PY - 2003/6/1

Y1 - 2003/6/1

N2 - The addition of atrial natriuretic peptide (ANP) to isolated human adipocytes in primary culture from very obese individuals resulted in an inhibition of leptin release after a 24- or 48-hr incubation. There was also an inhibition of leptin release by isoproterenol (ISO) that was partially reversed by insulin, whereas the inhibition due to ANP was unaffected. Similar results were seen with N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulphonamide (H-89), which is a cell-permeable inhibitor of protein kinase A. H-89 markedly reduced the effects of ISO on both lipolysis and leptin release without affecting the stimulation of lipolysis or the inhibition of leptin release due to ANP. Inhibition of endogenous nitric oxide formation using Nω-nitro-L-arginine resulted in a 20% increase in leptin release over 48hr, which suggests that the nitric oxide/cyclic GMP pathway might play a small role in the regulation of endogenous leptin release. Similarly, the addition of the nitric oxide donor (Z)-1-[2-aminoethyl)-N-(2-aminoethyl)diazen-1-ium-1,2-diolate (DETA NONOate) at 0.1 or 1μM to explants of human adipose tissue enhanced lipolysis by 29%. Our data demonstrate that the lipolytic effect of ANP is probably secondary to stimulation of cyclic GMP accumulation in human adipocytes, and this is accompanied by an inhibition of leptin release.

AB - The addition of atrial natriuretic peptide (ANP) to isolated human adipocytes in primary culture from very obese individuals resulted in an inhibition of leptin release after a 24- or 48-hr incubation. There was also an inhibition of leptin release by isoproterenol (ISO) that was partially reversed by insulin, whereas the inhibition due to ANP was unaffected. Similar results were seen with N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulphonamide (H-89), which is a cell-permeable inhibitor of protein kinase A. H-89 markedly reduced the effects of ISO on both lipolysis and leptin release without affecting the stimulation of lipolysis or the inhibition of leptin release due to ANP. Inhibition of endogenous nitric oxide formation using Nω-nitro-L-arginine resulted in a 20% increase in leptin release over 48hr, which suggests that the nitric oxide/cyclic GMP pathway might play a small role in the regulation of endogenous leptin release. Similarly, the addition of the nitric oxide donor (Z)-1-[2-aminoethyl)-N-(2-aminoethyl)diazen-1-ium-1,2-diolate (DETA NONOate) at 0.1 or 1μM to explants of human adipose tissue enhanced lipolysis by 29%. Our data demonstrate that the lipolytic effect of ANP is probably secondary to stimulation of cyclic GMP accumulation in human adipocytes, and this is accompanied by an inhibition of leptin release.

UR - http://www.scopus.com/inward/record.url?scp=0037716436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037716436&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(03)00154-0

DO - 10.1016/S0006-2952(03)00154-0

M3 - Article

VL - 65

SP - 1883

EP - 1888

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -